Pfizer Inc.
BCKDK inhibitors

Abstract:

Described herein are compounds of Formula I, ##STR00001## wherein R.sup.1, R.sup.2, and R.sup.3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.